A New Horizon in Achondroplasia: Oral Therapy Shows Promise in Phase 3 Trials

February 13, 2026

PALO ALTO, Calif. — In a development that could fundamentally shift the treatment landscape for skeletal dysplasia, BridgeBio Pharma announced this week that its experimental oral medication, infigratinib, significantly increased growth rates in children with achondroplasia. The Phase 3 PROPEL 3 study met its primary goal, showing that children taking the once-daily pill grew an average of 1.74 centimeters more per year than those receiving a placebo. Beyond height, the trial yielded a first-of-its-kind result: a statistically significant improvement in body proportionality for younger children, potentially addressing the physical complications associated with the condition.

Achondroplasia is the most common form of disproportionate short stature, affecting approximately 1 in 15,000 to 40,000 live births. It is caused by a genetic mutation in the FGFR3 gene, which sends overly aggressive signals to the cartilage, slowing down bone growth.

Breaking the “Height-Only” Barrier

The 52-week trial enrolled children aged 3 to under 18 who still have open growth plates. While the primary focus of such studies is often Annualized Height Velocity (AHV)—a measure of how many centimeters a child grows in a year—this study looked deeper into the skeletal architecture.

In a pre-specified analysis of participants aged 3 to 8, researchers found that infigratinib improved the ratio between the upper and lower body. In achondroplasia, the limbs (particularly the upper arms and thighs) are typically shorter in proportion to the trunk.

“Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone,” noted Dr. Ravi Savarirayan, MD, PhD, lead investigator and researcher at the Murdoch Children’s Research Institute.

The improvement in proportionality is clinically significant because the physical challenges of achondroplasia—such as reaching for objects, personal hygiene, and certain mobility tasks—are often tied to limb length rather than just total height.

Safety and Tolerability

For parents and clinicians, safety is the paramount concern in pediatric drug development. BridgeBio reported that there were no serious adverse events related to the drug during the study.

The most notable side effect was mild, transient hyperphosphatemia (elevated phosphate levels in the blood), which occurred in a small percentage of participants. Crucially, these cases did not require the children to stop the treatment or even reduce their dosage. No children discontinued the trial due to side effects, suggesting the oral pill is well-tolerated by the pediatric population.

Comparing the Options: Injections vs. Oral Pills

Currently, the primary pharmacological treatment for achondroplasia is vosoritide (Voxzogo), an injectable therapy. While effective, daily injections can be a significant burden for families and a source of anxiety for young children.

Industry analysts have noted that the 1.74 cm growth improvement seen with infigratinib compares favorably to data seen in previous trials of injectable therapies. However, the most immediate “game changer” may be the delivery method itself.

“A safe daily oral option is often preferred for young children and could be a game changer,” said Justin To, a BridgeBio executive, in a statement to Reuters.

If authorized, infigratinib would be the first oral therapy available for this condition, offering a less invasive alternative for families managing a lifelong genetic condition.

The Road Ahead: Regulatory Approval

BridgeBio plans to submit its findings to regulatory authorities in the United States and Europe in the second half of 2026. If the process remains on track, the drug could reach the market shortly thereafter.

However, medical experts urge a balanced view of these “topline” results. While the data is promising, the full study has not yet undergone the rigorous peer-review process in a medical journal.

Key limitations to consider include:

• Long-term Efficacy: Growth velocity can change as children hit puberty; long-term data will be needed to see if these gains are sustained.

• Functional Outcomes: While proportionality improved, further study is required to determine if this translates to better long-term physical function or a reduction in necessary surgeries.

• Individual Variation: Genetic conditions manifest differently in every child, and “average” growth increases do not guarantee the same result for every patient.

What This Means for Families

For families living with achondroplasia, the focus is increasingly shifting from “making children taller” to improving overall quality of life. Clinicians recommend that parents use these new developments as a starting point for conversations with a multi-disciplinary medical team, including pediatric endocrinologists, geneticists, and orthopedic surgeons.

The goal of treatment should be holistic, considering factors like:

• Sleep-disordered breathing (apnea)

• Spinal health (preventing stenosis)

• Mobility and independent functioning

As we move toward a future with multiple therapeutic options, the choice between an oral pill or an injection—or no pharmacological intervention at all—will remain a highly personal decision for each family.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

1. Reuters. “BridgeBio’s oral drug improves growth in children with dwarfism in late-stage study.” Feb 12, 2026.